Literature DB >> 25995391

Effective reduction of fluoroscopy duration by using an advanced electroanatomic-mapping system and a standardized procedural protocol for ablation of atrial fibrillation: 'the unleaded study'.

Sven Knecht1, Christian Sticherling1, Tobias Reichlin1, Nikola Pavlovic2, Aline Mühl1, Beat Schaer1, Stefan Osswald1, Michael Kühne3.   

Abstract

AIMS: It is recommended to keep exposure to ionizing radiation as low as reasonably achievable. The aim of this study was to determine whether fluoroscopy-free mapping and ablation using a standardized procedural protocol is feasible in patients undergoing pulmonary vein isolation (PVI). METHODS AND
RESULTS: Sixty consecutive patients were analysed: Thirty consecutive patients undergoing PVI using Carto3 were treated using a standardized procedural fluoroscopy protocol with X-ray being disabled after transseptal puncture (Group 1) and compared with a set of previous 30 consecutive patients undergoing PVI without a specific recommendation regarding the use of fluoroscopy (Group 2). The main outcome measures were the feasibility of fluoroscopy-free mapping and ablation, total fluoroscopy time, total dose area product (DAP), and procedure time. Sixty patients (age 60 ± 10 years, 73% male, ejection fraction 0.55 ± 0.09, left atrium 42 ± 8 mm) were included. In Group 1, total fluoroscopy time was 4.2 (2.6-5.6) min and mapping and ablation during PVI without using fluoroscopy was feasible in 29 of 30 patients (97%). In Group 2, total fluoroscopy time was 9.3 (6.4-13.9) min (P < 0.001). Total DAP was 13.2 (6.2-22.2) Gy*cm(2) in Group 1 compared with 17.5 (11.7-29.7) Gy*cm(2) in Group 2 (P = 0.036). Total procedure time did not differ between Groups 1 (133 ± 37 min) and 2 (134 ± 37 min, P = 0.884).
CONCLUSION: Performing mapping and ablation guided by an electroanatomic-mapping system during PVI without using fluoroscopy after transseptal puncture using a standardized procedural protocol is feasible in almost all patients and is associated with markedly decreased total fluoroscopy duration and DAP. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2015. For permissions please email: journals.permissions@oup.com.

Entities:  

Keywords:  Atrial fibrillation; Fluoroscopy; Mapping systems; Pulmonary vein isolation; Radiation

Mesh:

Year:  2015        PMID: 25995391     DOI: 10.1093/europace/euv006

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  5 in total

1.  Fluoroscopy-free AF ablation using transesophageal echocardiography and electroanatomical mapping technology.

Authors:  Benjamin O'Brien; Damian C Balmforth; Ross J Hunter; Richard J Schilling
Journal:  J Interv Card Electrophysiol       Date:  2017-11-14       Impact factor: 1.900

2.  High-power short-duration ablation index-guided pulmonary vein isolation protocol using a single catheter.

Authors:  Patrick Badertscher; Sven Knecht; Florian Spies; Gian Völlmin; Beat Schaer; Nicolas Schärli; Flurina Bosshard; Stefan Osswald; Christian Sticherling; Michael Kühne
Journal:  J Interv Card Electrophysiol       Date:  2022-05-20       Impact factor: 1.900

3.  Atrial Fibrillation Ablation Without Fluoroscopy: Because We Can.

Authors:  Rahul N Doshi
Journal:  J Innov Card Rhythm Manag       Date:  2018-11-15

4.  Fluoroscopy-Free Pulmonary Vein Isolation in Patients with Atrial Fibrillation and a Patent Foramen Ovale Using Solely an Electroanatomic Mapping System.

Authors:  Michael Kühne; Sven Knecht; Aline Mühl; Tobias Reichlin; Nikola Pavlović; Arnheid Kessel-Schaefer; Beat A Kaufmann; Beat Schaer; Christian Sticherling; Stefan Osswald
Journal:  PLoS One       Date:  2016-01-28       Impact factor: 3.240

5.  SANS FLUORO Optimized: A Case Report of Pulmonary Vein Isolation in a Patient with Cardiac Resynchronization Therapy Defibrillator and the Optimizer™ III Device.

Authors:  Hyacinth C Percell; Lynn Saeger; Erin Sharpe; Rose Saalfeld; Robert L Percell
Journal:  J Innov Card Rhythm Manag       Date:  2020-05-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.